Futu News, June 5: $LIULIUMEI (06658.HK)$The company announced that the IPO subscription period will run from June 5 to June 10. It plans to globally offer approximately 11.4641 million shares, with listing expected on June 15.
Company Overview
The company is a fruit snack business focused exclusively on preserved plum products. It is also committed to promoting plum culture by offering snacks made with natural ingredients. Guided by its plum-centric product development strategy, the company has built a diversified portfolio of preserved plum products, ranging from classic lines crafted using traditional techniques to innovative offerings infused with various flavors. Since launching its flagship brand 'Liu Liu Mei' in 2001, the company has been dedicated to developing high-quality preserved plum products and exploring the culinary potential of the plum’s distinctive tartness.
According to Frost & Sullivan, in 2024, the company ranked first in retail sales within China's fruit snack sector, holding a market share of 4.9%. Since its launch in 2019, the company's plum jelly has quickly captured consumer attention thanks to its naturally refreshing taste.
Financial Summary
The company's revenue increased by 22.2% from RMB 13,220 million in 2023 to RMB 16,160 million in 2024, and further rose by 5.9% to RMB 17,107 million in 2025. Gross profit grew by 10.0% from RMB 5,297 million in 2023...
Company Overview
The company is a fruit snack business focused exclusively on preserved plum products. It is also committed to promoting plum culture by offering snacks made with natural ingredients. Guided by its plum-centric product development strategy, the company has built a diversified portfolio of preserved plum products, ranging from classic lines crafted using traditional techniques to innovative offerings infused with various flavors. Since launching its flagship brand 'Liu Liu Mei' in 2001, the company has been dedicated to developing high-quality preserved plum products and exploring the culinary potential of the plum’s distinctive tartness.
According to Frost & Sullivan, in 2024, the company ranked first in retail sales within China's fruit snack sector, holding a market share of 4.9%. Since its launch in 2019, the company's plum jelly has quickly captured consumer attention thanks to its naturally refreshing taste.
Financial Summary
The company's revenue increased by 22.2% from RMB 13,220 million in 2023 to RMB 16,160 million in 2024, and further rose by 5.9% to RMB 17,107 million in 2025. Gross profit grew by 10.0% from RMB 5,297 million in 2023...
9
32
In 2026, the global tech capital market is reaching a historic inflection point. As artificial intelligence and commercial spaceflight converge deeply, Elon Musk’s highly anticipated company SpaceX is gradually lifting the veil on its entry into the capital markets.
Latest IPO update: Price locked in advance, racing toward the largest IPO in history
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), Musk has made a rare move on Wall Street—officially launching its initial public offering roadshow at an issue price of $135 per share.
Typically, IPO pricing is dynamically determined during the roadshow based on institutional investors’ subscription interest. SpaceX’s unconventional approach—bypassing this norm and directly locking in a single target price for the roadshow—demonstrates management’s absolute confidence in strong market demand.Notably, as a prelude to this capital frenzy, a 2x leveraged ETF tracking SpaceX (ticker: SPCH) is expected to debut on the market either on SpaceX’s listing day or shortly thereafter.
According to the current offering schedule, shares are expected to be listed onJune 12, 2026Officially listed for trading, with the Nasdaq ticker symbol set as"SPCX"。
Valuation and scale:SpaceX's total market capitalization will reach an astonishing$1.77 trillion(over $1.8 trillion on a fully diluted basis). This valuation already surpasses Tesla—also owned by Musk—at approximately $1.6 trillion, making SpaceX the most valuable publicly traded company in the U.S....
Latest IPO update: Price locked in advance, racing toward the largest IPO in history
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), Musk has made a rare move on Wall Street—officially launching its initial public offering roadshow at an issue price of $135 per share.
Typically, IPO pricing is dynamically determined during the roadshow based on institutional investors’ subscription interest. SpaceX’s unconventional approach—bypassing this norm and directly locking in a single target price for the roadshow—demonstrates management’s absolute confidence in strong market demand.Notably, as a prelude to this capital frenzy, a 2x leveraged ETF tracking SpaceX (ticker: SPCH) is expected to debut on the market either on SpaceX’s listing day or shortly thereafter.
According to the current offering schedule, shares are expected to be listed onJune 12, 2026Officially listed for trading, with the Nasdaq ticker symbol set as"SPCX"。
Valuation and scale:SpaceX's total market capitalization will reach an astonishing$1.77 trillion(over $1.8 trillion on a fully diluted basis). This valuation already surpasses Tesla—also owned by Musk—at approximately $1.6 trillion, making SpaceX the most valuable publicly traded company in the U.S....
114
24
314
牛友們好呀！ $LONGBIO-B (01779.HK)$ $DAJIN (01081.HK)$ $LUNG FUNG GROUP (02290.HK)$ 已經公佈中籤，牛牛新股君統計了富途客戶獲配情況，牛友們快來查收![]()
![]()
天辰生物-B富途客戶獲配情況如下：
大金重工富途客戶獲配情況如下：
龍豐集團富途客戶獲配情況如下：
預告：以上3隻IPO即將於6月4日16:15-18:30進行暗盤交易，6月5日正式上市。
抽新股黃金季已到！抽新股用富途，0利息、0手續費、0現金認購。現參與活動有機會免1年抽新股費用，快來體驗吧>>
天辰生物-B富途客戶獲配情況如下：
大金重工富途客戶獲配情況如下：
龍豐集團富途客戶獲配情況如下：
預告：以上3隻IPO即將於6月4日16:15-18:30進行暗盤交易，6月5日正式上市。
抽新股黃金季已到！抽新股用富途，0利息、0手續費、0現金認購。現參與活動有機會免1年抽新股費用，快來體驗吧>>
+1
66
7
17
Futu News, June 3: $SHOUGANG LANZA (02553.HK)$ announced its allotment results, pricing shares at HK$14.6 each, issuing a total of 40 million shares, with a board lot size of 200 shares, officially listing today.
On the previous trading day, Shougang Lanzze's grey market closed up 146.58% at HK$36. With a board lot of 200 shares, investors made HK$4,280 per lot before fees.
During the public offering phase, Shougang Lanzze received 1,421.54x subscription. Following reallocation, the final number of shares allocated to the public offering was 6 million shares, representing approximately 15% of the total offering. A total of approximately 109,100 valid applications were received, with around 21,872 applications processed, and the approximate percentage of applicants who applied for one lot and received an allotment was 2% of total applications.
Additionally, during the international placement phase, Shougang Lanzze received 0.95x subscription. The final number of shares allocated to the international offering was 34 million shares, representing 85% of the total offering. Futu News has compiled the relevant data in the table below:
Company Overview
The company operates in the carbon capture, utilization, and storage (CCUS) industry, primarily focusing on producing low-carbon products such as ethanol and microbial protein through carbon capture and utilization technologies, and providing integrated low-carbon solutions. Since its establishment in 2011, the company has been deeply engaged in the CCUS sector. According to Frost & Sullivan, the company is the first in the CCUS industry to utilize...
On the previous trading day, Shougang Lanzze's grey market closed up 146.58% at HK$36. With a board lot of 200 shares, investors made HK$4,280 per lot before fees.
During the public offering phase, Shougang Lanzze received 1,421.54x subscription. Following reallocation, the final number of shares allocated to the public offering was 6 million shares, representing approximately 15% of the total offering. A total of approximately 109,100 valid applications were received, with around 21,872 applications processed, and the approximate percentage of applicants who applied for one lot and received an allotment was 2% of total applications.
Additionally, during the international placement phase, Shougang Lanzze received 0.95x subscription. The final number of shares allocated to the international offering was 34 million shares, representing 85% of the total offering. Futu News has compiled the relevant data in the table below:
Company Overview
The company operates in the carbon capture, utilization, and storage (CCUS) industry, primarily focusing on producing low-carbon products such as ethanol and microbial protein through carbon capture and utilization technologies, and providing integrated low-carbon solutions. Since its establishment in 2011, the company has been deeply engaged in the CCUS sector. According to Frost & Sullivan, the company is the first in the CCUS industry to utilize...
+1
10
1
17
Columns Allotment Results Announced | Allocation Details for Futu Clients in Shougang Langze IPO Released!
Hello, fellow investors! $SHOUGANG LANZA (02553.HK)$ The allotment results have been announced! Niu Niu Xin Gu Jun has compiled the allocation details for Futu clients—fellow investors, check it out now!![]()
![]()
Allocation details for Futu clients in the Shougang Langze IPO are as follows:
Preview: Shougang Langze will begin grey market trading on June 2 from 16:15 to 18:30, and officially list on June 3.
$LUNG FUNG GROUP (02290.HK)$ 、 $LONGBIO-B (01779.HK)$ 、 $DAJIN (01081.HK)$ Hot subscription ongoing! The offering will close on June 2 at 10:00, with grey market trading scheduled for June 4 from 16:15 to 18:30, and official listing on June 5.
The golden season for subscribing to new stocks has arrived! Use Futu to subscribe with 0 interest, 0 handling fees, and 0 cash subscription. Participate now for a chance to have your new stock subscription fees waived for a year,come and experience it now >>
Allocation details for Futu clients in the Shougang Langze IPO are as follows:
Preview: Shougang Langze will begin grey market trading on June 2 from 16:15 to 18:30, and officially list on June 3.
$LUNG FUNG GROUP (02290.HK)$ 、 $LONGBIO-B (01779.HK)$ 、 $DAJIN (01081.HK)$ Hot subscription ongoing! The offering will close on June 2 at 10:00, with grey market trading scheduled for June 4 from 16:15 to 18:30, and official listing on June 5.
The golden season for subscribing to new stocks has arrived! Use Futu to subscribe with 0 interest, 0 handling fees, and 0 cash subscription. Participate now for a chance to have your new stock subscription fees waived for a year,come and experience it now >>
28
14
7
In May 2026, the Hong Kong IPO market continued its explosive recovery trend seen since the beginning of the year, exhibiting overallhigh issuance activity, large fundraising scale, optimized industry composition, and strong institutional recognitionas its four defining characteristics, with market activity firmly ranking among the top global capital markets.
According to Wind data, as of the end of May, the total funds raised from Hong Kong IPOs this year have exceeded HK$163 billion, a year-on-year increase of approximately 110%. The number of new listings reached 60, significantly higher than the same period last year. Institutional participation surged notably in May. Wind data shows that cornerstone investors accounted for over 40% of subscriptions for this year’s new listings—the highest level since 2018—with overseas capital comprising more than half of cornerstone subscription volume. Middle Eastern sovereign wealth funds, top-tier global asset managers, and industrial-chain-focused capital have all entered the market en masse, highlighting the growing institutionalization of new listings.
May’s new listings delivered strong returns, with Yifly Technology crowned the all-time oversubscription champion
This month’s new listings were heavily concentrated in hard-tech sectors, reflecting increasingly distinct industrial characteristics, with AI supply chains and robotics emerging as dominant listing themes. Additionally, the A+H dual-listing wave continues to gain momentum—15 A-share industry leaders have already listed in Hong Kong this year. High-end manufacturing and export-oriented tech firms are accelerating their pace of accessing Hong Kong markets via the A+H route, becoming a core driver of Hong Kong IPO growth.
May’s Hong Kong new listings delivered notably strong first-day returns: 11 out of 13 debuted in positive territory, with 10 rising more than 75%, yielding a win rate exceeding...
According to Wind data, as of the end of May, the total funds raised from Hong Kong IPOs this year have exceeded HK$163 billion, a year-on-year increase of approximately 110%. The number of new listings reached 60, significantly higher than the same period last year. Institutional participation surged notably in May. Wind data shows that cornerstone investors accounted for over 40% of subscriptions for this year’s new listings—the highest level since 2018—with overseas capital comprising more than half of cornerstone subscription volume. Middle Eastern sovereign wealth funds, top-tier global asset managers, and industrial-chain-focused capital have all entered the market en masse, highlighting the growing institutionalization of new listings.
May’s new listings delivered strong returns, with Yifly Technology crowned the all-time oversubscription champion
This month’s new listings were heavily concentrated in hard-tech sectors, reflecting increasingly distinct industrial characteristics, with AI supply chains and robotics emerging as dominant listing themes. Additionally, the A+H dual-listing wave continues to gain momentum—15 A-share industry leaders have already listed in Hong Kong this year. High-end manufacturing and export-oriented tech firms are accelerating their pace of accessing Hong Kong markets via the A+H route, becoming a core driver of Hong Kong IPO growth.
May’s Hong Kong new listings delivered notably strong first-day returns: 11 out of 13 debuted in positive territory, with 10 rising more than 75%, yielding a win rate exceeding...
14
21
Hello, fellow investors! Niu Niu IPO Tracker brings you the hottest Hong Kong IPOs for June and 2026—be sure to check them out!![]()
![]()
As of this writing, $SHOUGANG LANZA (02553.HK)$ has closed its subscription period, will conduct grey market trading from 16:15 to 18:30 on June 2, and officially list on June 3.
$LUNG FUNG GROUP (02290.HK)$ 、 $LONGBIO-B (01779.HK)$ 、 $DAJIN (01081.HK)$ is now open for hot subscription, closing at 10:00 on June 2, with grey market trading scheduled from 16:15 to 18:30 on June 4, and official listing on June 5.
Shougang Langze: Shougang Langze is a company operating in the carbon capture, utilization, and storage (CCUS) sector, primarily focused on producing low-carbon products such as ethanol and microbial protein through carbon capture and utilization technologies, and offering integrated low-carbon solutions. Since its establishment in 2011, the company has specialized in the CCUS industry. According to Frost & Sullivan, it is the first company in the CCUS industry to commercialize and scale low-carbon product production using proven synthetic biology technology.
Tianchen Bio: Tianchen Bio is a clinical-stage biopharmaceutical company founded in 2020, headquartered in Shanghai and Changshu, Suzhou, China. It focuses on the independent discovery and development of biologics targeting allergic and autoimmune diseases. The company...
As of this writing, $SHOUGANG LANZA (02553.HK)$ has closed its subscription period, will conduct grey market trading from 16:15 to 18:30 on June 2, and officially list on June 3.
$LUNG FUNG GROUP (02290.HK)$ 、 $LONGBIO-B (01779.HK)$ 、 $DAJIN (01081.HK)$ is now open for hot subscription, closing at 10:00 on June 2, with grey market trading scheduled from 16:15 to 18:30 on June 4, and official listing on June 5.
Shougang Langze: Shougang Langze is a company operating in the carbon capture, utilization, and storage (CCUS) sector, primarily focused on producing low-carbon products such as ethanol and microbial protein through carbon capture and utilization technologies, and offering integrated low-carbon solutions. Since its establishment in 2011, the company has specialized in the CCUS industry. According to Frost & Sullivan, it is the first company in the CCUS industry to commercialize and scale low-carbon product production using proven synthetic biology technology.
Tianchen Bio: Tianchen Bio is a clinical-stage biopharmaceutical company founded in 2020, headquartered in Shanghai and Changshu, Suzhou, China. It focuses on the independent discovery and development of biologics targeting allergic and autoimmune diseases. The company...
16
5
15
Futu News, May 29: $CREALITY (03388.HK)$announced the allocation results, pricing shares at HK$18.8 each, issuing a total of 73.4275 million shares, with a board lot size of 150 shares, officially listing today.
On the previous trading day, Creality 3D’s shares rose over 70% in the grey market, closing at HK$32.08 per share. With a board lot of 150 shares, investors gained HK$1,992 per lot before accounting for fees.
During the public offering stage, Creality 3D received 3,829.42x subscription. The final number of shares allocated to the public offering was 7.3428 million shares, representing approximately 10% of the total offering. A total of approximately 251,400 valid applications were received, with about 44,336 applications processed. The approximate percentage of applicants who received one lot out of all applications was 3%.
Additionally, during the international placement stage, Creality 3D received 26.8x subscription. The final number of shares allocated to international investors was 66.0847 million shares, equivalent to 90% of the total offering. Futu News has compiled the relevant data in the table below:
Company Overview
The company is a global provider of consumer-grade 3D printing products and services. Its product and service portfolio primarily includes: 3D printers, 3D printing materials, 3D scanners, laser engravers, accessories and others, as well as various services offered through Creality Cloud (the company’s dedicated platform for 3D printing content). Furthermore, the company plans to launch Nexbie in August 2025, a platform focused on 3D creation...
On the previous trading day, Creality 3D’s shares rose over 70% in the grey market, closing at HK$32.08 per share. With a board lot of 150 shares, investors gained HK$1,992 per lot before accounting for fees.
During the public offering stage, Creality 3D received 3,829.42x subscription. The final number of shares allocated to the public offering was 7.3428 million shares, representing approximately 10% of the total offering. A total of approximately 251,400 valid applications were received, with about 44,336 applications processed. The approximate percentage of applicants who received one lot out of all applications was 3%.
Additionally, during the international placement stage, Creality 3D received 26.8x subscription. The final number of shares allocated to international investors was 66.0847 million shares, equivalent to 90% of the total offering. Futu News has compiled the relevant data in the table below:
Company Overview
The company is a global provider of consumer-grade 3D printing products and services. Its product and service portfolio primarily includes: 3D printers, 3D printing materials, 3D scanners, laser engravers, accessories and others, as well as various services offered through Creality Cloud (the company’s dedicated platform for 3D printing content). Furthermore, the company plans to launch Nexbie in August 2025, a platform focused on 3D creation...
+1
6
17
Futu News, May 28: $LONGBIO-B (01779.HK)$The company announced that the IPO subscription period will run from May 28 to June 2. It plans to offer approximately 14.1931 million shares globally, with listing expected on June 5.
Company Overview
The company is a clinical-stage biopharmaceutical company founded in 2020, headquartered in Shanghai and Changshu, Suzhou, China. It primarily focuses on the independent discovery and development of biologics targeting allergic and autoimmune diseases. The company has built a comprehensive pipeline of biologic drug candidates covering rhinology, dermatology, respiratory, hematology, nephrology, and other autoimmune disease areas.
The company's lead product, LP-003, is an anti-IgE antibody featuring a novel sequence design. LP-003 primarily functions by blocking free IgE in blood and tissues, thereby inhibiting IgE-mediated allergic reactions. IgE is central to the mechanism of Type I hypersensitivity. Type I hypersensitivity, triggered by allergens in various organs, causes seasonal allergic rhinitis (AR), allergic asthma, chronic spontaneous urticaria (CSU), food allergies, and other allergic conditions.
Financial Summary
For the years 2024 and 2025, our total comprehensive losses amounted to RMB 137.3 million and RMB 175.6 million, respectively.
Use of Proceeds
Regarding the use of proceeds, Tiance Bio-B expects net proceeds from the global offering to be approximately RMB 125 million...
Company Overview
The company is a clinical-stage biopharmaceutical company founded in 2020, headquartered in Shanghai and Changshu, Suzhou, China. It primarily focuses on the independent discovery and development of biologics targeting allergic and autoimmune diseases. The company has built a comprehensive pipeline of biologic drug candidates covering rhinology, dermatology, respiratory, hematology, nephrology, and other autoimmune disease areas.
The company's lead product, LP-003, is an anti-IgE antibody featuring a novel sequence design. LP-003 primarily functions by blocking free IgE in blood and tissues, thereby inhibiting IgE-mediated allergic reactions. IgE is central to the mechanism of Type I hypersensitivity. Type I hypersensitivity, triggered by allergens in various organs, causes seasonal allergic rhinitis (AR), allergic asthma, chronic spontaneous urticaria (CSU), food allergies, and other allergic conditions.
Financial Summary
For the years 2024 and 2025, our total comprehensive losses amounted to RMB 137.3 million and RMB 175.6 million, respectively.
Use of Proceeds
Regarding the use of proceeds, Tiance Bio-B expects net proceeds from the global offering to be approximately RMB 125 million...
12
25
Futu News, May 28: $LUNG FUNG GROUP (02290.HK)$ announced in a filing that it will open its IPO subscription from May 28 to June 2, offering approximately 125 million shares globally, with an expected listing date of June 5.
Company Overview
Lung Fung Group is a leading Hong Kong-based retail chain operating under the 'Lung Fung' brand, specializing in cosmetics, health supplements, and pharmaceutical products. As of the latest practicable date, the company operates 31 retail stores in Hong Kong and multiple online sales platforms, focusing on delivering a wide selection of high-value products to customers. With over 30 years of experience, the company has developed a strong capability to effectively identify and respond to consumer demand in the local retail market, establishing itself as a one-stop supplier of cosmetics, health supplements, and pharmaceuticals.
The company possesses robust supply chain procurement capabilities, sourcing from over 600 suppliers—including international brand manufacturers and authorized distributors—as of November 30, 2025, ensuring stable and timely product availability. In each of the fiscal years 2023, 2024, and 2025, three of the company’s top five suppliers had maintained business relationships exceeding 15 years.
Financial Summary
For the fiscal years ended 2023, 2024, and 2025, Lung Fung Group reported total revenues of HK$10,940 million, HK$20,207 million, and HK$24,605 million, respectively...
Company Overview
Lung Fung Group is a leading Hong Kong-based retail chain operating under the 'Lung Fung' brand, specializing in cosmetics, health supplements, and pharmaceutical products. As of the latest practicable date, the company operates 31 retail stores in Hong Kong and multiple online sales platforms, focusing on delivering a wide selection of high-value products to customers. With over 30 years of experience, the company has developed a strong capability to effectively identify and respond to consumer demand in the local retail market, establishing itself as a one-stop supplier of cosmetics, health supplements, and pharmaceuticals.
The company possesses robust supply chain procurement capabilities, sourcing from over 600 suppliers—including international brand manufacturers and authorized distributors—as of November 30, 2025, ensuring stable and timely product availability. In each of the fiscal years 2023, 2024, and 2025, three of the company’s top five suppliers had maintained business relationships exceeding 15 years.
Financial Summary
For the fiscal years ended 2023, 2024, and 2025, Lung Fung Group reported total revenues of HK$10,940 million, HK$20,207 million, and HK$24,605 million, respectively...
20
5
61
![[empty]](https://static.futunn.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.futunn.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,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)